<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817192</url>
  </required_header>
  <id_info>
    <org_study_id>EC-120888</org_study_id>
    <nct_id>NCT01817192</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Razor Genomics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Encore Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Encore Clinical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal treatment for Stage I or Stage IIA non-small cell lung cancer (NSCLC) remains
      controversial. Radiographic surveillance alone has been recommended for stage I and stage IIA
      patients after the tumor is removed surgically from the lung, and this standard has been
      based on the fact that no previous clinical trial has demonstrated a benefit for Stage I or
      Stage IIA NSCLC patients who receive post-operative chemotherapy. These patients, however,
      have a substantial risk of death within five years after operation, ranging from
      approximately 30% to 45%, largely due to metastatic disease that is present immediately after
      surgery but that is undetectable by conventional methods. Some leading organizations
      therefore currently recommend post-operative chemotherapy as an alternative standard of care
      in Stage I or Stage IIA NSCLC patients who are considered to be at particularly high-risk. Up
      until now, however, there has not been a well-validated means to identify stage I and stage
      IIA NSCLC patients at high risk of death within five years after operation. A new prognostic
      tool, a 14-Gene Prognostic Assay, which has been validated and definitively demonstrated in
      large scale studies to identify intermediate and high-risk stage I or Stage IIA patients with
      non-squamous NSCLC, is now available to all clinicians through a CLIA-certified laboratory.
      It is therefore now possible to compare the outcomes of patients randomly assigned to one or
      the other of these competing standards of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2020</start_date>
  <completion_date type="Anticipated">May 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Results of 14-Gene prognostic assay will not be revealed to the patient. Low risk patients will be observed, intermediate and high risk patients will be randomized to observation or four cycles of a cisplatin-based doublet therapy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-operative observation of Stage I or Stage IIA non squamous non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as low risk will be observation. Those patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant Chemotherapy is a current standard of care for intermediate or high-risk Stage I or Stage IIA non-squamous non-small cell lung cancer. Patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Observation Arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant Chemotherapy</intervention_name>
    <description>Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC cisplatin-based doublet.</description>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiographic surveillance</intervention_name>
    <description>Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>14-Gene Prognostic Assay</intervention_name>
    <description>This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.</description>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥ 18 years

          -  Adequate tissue sample for the 14-Gene Prognostic Assay

          -  Histologically documented completely resected (R0) Stage I or Stage IIA non-squamous
             NSCLC

          -  Life expectancy excluding NSCLC diagnosis ≥ 5 years

          -  ECOG performance status 0-1

          -  Adequate haematological function:

               1. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3 AND

               2. Platelet count ≥ 100000 cells/mm3 AND

               3. Haemoglobin ≥ 9 g/dL (may be transfused to maintain or exceed this level)

          -  Adequate liver function:

               1. Total bilirubin &lt; 1.5 x upper limit of normal (ULN) AND

               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 x ULN

          -  Adequate renal function, with Serum creatinine ≤ 1.5 x ULN

          -  Completely healed incisions

        Exclusion Criteria:

          -  Final pathologic diagnosis of purse squamous cell histology, pure small cell or pure
             neuroendocrine histology, or any combination of only these three histologies.

          -  Evidence of greater than stage II A pathologic staging

          -  Evidence of incomplete resection

          -  Pregnant or lactating women

          -  Unwilling to use an effective means of contraception

          -  Active infection, either systemic or at site of primary resection

          -  Prior systemic chemotherapy or anti-cancer agent

          -  Any pre- or post-operative radiotherapy

          -  Malignancies other than NSCLC within 5 years prior to randomization, except for
             adequately treated CIS of the cervix, basal or squamous cell skin cancer, localized
             prostate cancer treated surgically, ductal carcinoma in situ treated surgically

          -  Treatment with any investigational drug or participation in another clinical trial
             within 28 days prior to enrollment

          -  Known hypersensitivity to any of the study treatment agents

          -  Evidence of any other disease including infection that contraindicates the use of
             systemic cytotoxic chemotherapy or puts the patient at high risk for treatment related
             complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Spigel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarah Cannon, The Cancer Institute of HCA Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Mann, MD</last_name>
    <phone>650-535-0030</phone>
    <email>mmann@encoreclinical.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolyn Clary, RN</last_name>
    <phone>650-535-0030</phone>
    <email>cclary@encoreclinical.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leonard Cancer Institute</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92961</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathryn Irenze, RN</last_name>
      <phone>949-573-9492</phone>
      <email>kathryn.irenze@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Samer Kanaan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Miranda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard Cheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy McKenna</last_name>
      <phone>310-829-8618</phone>
      <email>kathy.mckenna@providence.org</email>
    </contact>
    <investigator>
      <last_name>Robert J McKenna, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karli Heasley, BPH</last_name>
      <phone>859-260-6464</phone>
      <email>karli.heasley@BHSI.COM</email>
    </contact>
    <investigator>
      <last_name>Firas Badin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Schell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Hicks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arvinda Padmanabhan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Phyllis Thornton</last_name>
      <phone>502-721-6030</phone>
      <email>phyllis.thornton@bhsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Denise Geiger</last_name>
      <phone>502-721-6030</phone>
      <email>karen.geiger@bhsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wangjian Zhong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leela Bhupalam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Code, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khalid Ghosheh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Hart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Huber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Paducah</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tammy Coursey</last_name>
      <phone>270-575-2413</phone>
      <email>tammy.coursey@bhsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Betty Kuiper</last_name>
      <phone>270-575-2928</phone>
      <email>bkuiper@bhsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Winston Chua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Lopez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Joplin Missouri</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esmeralda Carillo</last_name>
      <email>Esmeralda.Carrillo@mercy.net</email>
    </contact>
    <contact_backup>
      <last_name>Leah Klink</last_name>
      <email>Leah.Klink@mercy.net</email>
    </contact_backup>
    <investigator>
      <last_name>Samir Dalia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Croy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irving LaFrancis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rana Hawamdeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital South</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Lesko</last_name>
      <email>Janet.Lesko@Mercy.Net</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Brown</last_name>
      <email>Jennifer.Brown8@Mercy.Net</email>
    </contact_backup>
    <investigator>
      <last_name>Shaun C Donegan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minxiang Gu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaun B Hanson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jansed Agha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Oncology Research St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Cattoor</last_name>
      <email>Erin.Cattoor@mercy.net</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Black</last_name>
      <email>Jessica.Black@mercy.net</email>
    </contact_backup>
    <investigator>
      <last_name>Bethany Sleckman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsiao-Ou Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Finnie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heide Rodgers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Somasekhar Bandi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kavitha Kosuri, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Oncology Research Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sherry Freeland</last_name>
      <email>Sherry.Freeland@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Carla Kurkijian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jess Armor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abby Bova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordan Morton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Varghese, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Thompson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Smith</last_name>
      <phone>206-265-2937</phone>
      <email>andrew.smith@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Renae Koepke</last_name>
      <phone>206-386-2441</phone>
      <email>renae.koepke@swedish.org</email>
    </contact_backup>
    <investigator>
      <last_name>Adam J Bograd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Vallieres, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Louie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alex Farivar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralph Aye, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <reference>
    <citation>Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 3;379(9818):823-32. doi: 10.1016/S0140-6736(11)61941-7. Epub 2012 Jan 27.</citation>
    <PMID>22285053</PMID>
  </reference>
  <reference>
    <citation>Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 Jan;19(1):58-64. doi: 10.1016/j.cllc.2017.05.015. Epub 2017 May 31.</citation>
    <PMID>28645632</PMID>
  </reference>
  <reference>
    <citation>Kratz JR, Van den Eeden SK, He J, Jablons DM, Mann MJ. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA. 2012 Oct 24;308(16):1629-31. doi: 10.1001/jama.2012.13551.</citation>
    <PMID>23093159</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 16, 2013</study_first_submitted>
  <study_first_submitted_qc>March 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2013</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Squamous</keyword>
  <keyword>Adjuvant Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

